An analysis of the evidence underpinning the national comprehensive cancer network practice guidelines.
AMSTAR-2
Cancer screening
Clinical practice guidelines
PRISMA
Systematic reviews
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
05
07
2021
revised:
18
10
2021
accepted:
01
11
2021
pubmed:
29
11
2021
medline:
18
1
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
This study assesses the quality and completeness of systematic reviews (SRs) included by the National Comprehensive Cancer Network (NCCN) cancer screening clinical practice guidelines (CPGs). We evaluated SRs according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and AMSTAR-2 (A Measurement Tool to Assess systematic Reviews). Seven NCCN CPGs were included with 109 SRs. The mean PRISMA percent completeness of included SRs was 71 % (range 0.1-1.0). The mean AMSTAR-2 percent completeness was 56 % (range 0.05-0.99). Of the 70 SRs assessed via AMSTAR-2, 42 (60 %) received a "critically low" rating, 11 (15.7 %) received "low" ratings, and 17 (24.3 %) received "moderate". None of the SRs received a "high" rating. Lack of adherence to AMSTAR-2 and PRISMA reporting standards among the SRs included is prevalent. We suggest improved reporting of SR inclusion criteria and evaluation to bolster the reporting quality of SRs underpinning CPG recommendations.
Identifiants
pubmed: 34838981
pii: S1040-8428(21)00336-X
doi: 10.1016/j.critrevonc.2021.103549
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103549Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.